Glaxosmithkline Biologicals Sa

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Nouscom Ag

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Msd Italia S.r.l.

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

University of Copenhagen

Sabin Vaccine Institute

Istituto Di Recerche Di Biologia Moleculare P. Angeletti S.p.a.

Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.p.a.

Ceingebiotecnologie Avanzate Franco Salvatore Scarl

Alma Mater Studiorum-Universitá Di Bologna

Alfredo Nicosia

Riccardo Cortese

Stefano Colloca

Virginia Ammendola

Armin Lahm

Antonella Folgori

Alessandra Luzzago

Alessandra Vitelli

Gary J Nabel

Cheng Cheng

Nancy J Sullivan

Clement Asiedu

Maria Ambrosio

Andrew J Bett

David C Kaslow

John W Shiver

Emilio A Emini

Paolo Monaci

Maria Gabriella Campadelli

Agostino Cirillo

Annalisa Meola

Fabiana Grazioli

Bruno Bruni Ercole

Elisabetta Sporeno

Franco Felici

Elisabetta (deceased) Sporeno

Peter Johannes Holst

Anna Tramontano

Elisa Scarselli

Guido Leoni

Nicola Zambrano

Emanuele Sasso

Claudia De Lorenzo

Paolo Palazzolo, Legal Representative

Maria Rosaria Bassi

Anna Morena D'Alise

Ricardo Cortese

The present invention relates to antagonistic antigen binding proteins, a nucleic acid encoding the antagonistic binding protein, a recombinant expression vector comprising the nucleic acid molecule, a host cell comprising the vector, a method of making the antagonistic antigen binding protein, an antagonistic binding protein produced by the method and a pharmaceutical composition comprising the antagonistic binding protein, the nucleic acid or the vector. The present invention further relates to a kit comprising the pharmaceutical composition and use of the antagonistic binding protein in the treatment of cancer and/or chronic infectious diseases.

Antagonistic PD-1, PD-L1 and LAG-3 binding proteins

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Chimpanzee adenoviral vector-based filovirus vaccines

The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.

Expression systems

The present invention relates to a cell line, use of the cell line and a method for producing infectious viral particles using said cell line.

Eukaryotic cell line

This invention relates to a method of selecting a collection of frame-shift peptides (CFSPs) to produce a universal cancer vaccine peptide collection (CVP) for prophylaxis and treatment of patients with hereditary and sporadic micro-satellite instability (MSI) tumors. This invention relates as well to a method of producing a CVP by selecting a subset of frame-shift peptides (FSPs) from the CFSP and optionally modifying the FSP's amino acid (aa) sequence to generate modified FSPs (mFSPs). The invention further relates to nucleic acid collections encoding a CVP of FSPs and/or mFSPs in one or more vaccine vectors that can be used also simultaneously. These CVPs, nucleic acids and vectors are used for the prophylaxis or treatment of MSI cancers.

Universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers

The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.

Fusion peptides with antigens linked to short fragments of invariant chain(CD74)

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.

Poxviral vaccines

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

Adenovirus polynucleotides and polypeptides

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

Recombinant simian adenoviral vectors encoding a heterologous fiber protein and uses thereof

The present invention relates to novel adenovirus strains with a high immunogenicity and no pre-existing immunity in the general human population. The lack of pre-existing immunity is due to novel hypervariable regions in the adenoviral capsid protein hexon. The novel adenovirus strains also have an improved capacity for reproduction. The present invention provides nucleotide and amino acid sequences of these novel adenovirus strains, as well as recombinant viruses, virus-like particles and vectors based on these strains. Further provided are pharmaceutical compositions and medical uses in the therapy or prophylaxis of a disease, and methods for producing an adenovirus or virus-like particles utilizing the novel sequences, recombinant viruses, virus-like particles and vectors.

Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

Chimpanzee clade E adenovirus nucleic acid-and amino acid-sequences, vectors containing same, and uses thereof

Growing community of inventors

Rome, Italy

Alfredo Nicosia